A Randomized Trial Comparing 2 Methods for Rapid Induction of Cooling in Stroke Patients, Cold Infusions vs. RhinoChill (iCOOL 1)

University Hospital Heidelberg

Status and phase: Completed; Phase 2

Conditions: Ischemic Stroke; Hemorrhagic Stroke

Treatments: Device: RhinoChill; Drug: Cold crystalloid infusions, 0.9%NaCl or Ringer's solution

Study type: Interventional

Funder types: Other

Identifiers

NCT01573117

iCOOL 1

Details and patient eligibility

About

Mild hypothermia improves outcome in patients with global cerebral ischemia after cardiac arrest. Hypothermia seems promising also in other acute hypoxic-ischemic or in brain swelling associated cerebrovascular disease. The narrow-time-frame is a major issue ("time is brain"). To provide immediate cooling without delay, easy to use, mobile and effective methods are needed. Cold infusions (4 °C) are an accepted standard worldwide. The RhinoChill (BeneChill, USA) is a new device. A comparison of these two induction methods has never been done before. Neither was the effect of cold infusions on brain-temperature measured. For the first time iCOOL 1 compares feasibility, safety and efficacy of the two methods.

Enrollment: 20 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Sedation, intubation and mechanical ventilation
• Combined ICP-temperature-probe
• Indication to lower body temperature
• Age ≥ 18 years

Exclusion criteria

• Body weight > 120 kg
• Fever > 38.5°C
• Chronic sinusitis
• Current or past fracture or surgery of the paranasal sinuses
• Severe infection with bacteremia or sepsis ≤ 72 h
• Severe renal insufficiency
• Severe liver insufficiency
• Acute pulmonary embolism
• Acute myocardial infarction
• Severe cardiac insufficiency (NYHA ≥ III)
• Threatening ventricular dysrhythmia
• Cardiac dysrhythmia with bradycardia (heart rate < 50 /min, QTc > 450 ms, sick sinus syndrome, AV-block II-III°).
• Known hematologic disease with increased risk of thrombosis (e.g. cryoglobulinemia, cold agglutinins, sickle cell anemia)
• Known vasospastic vascular disorder (e.g. Raynaud's phenomenon or thromboangiitis obliterans)

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

20 participants in 2 patient groups

Cold infusions

Active Comparator group

Description:

Infusion of 2L cold crystalloid solution (4°C) over 30 minutes

Treatment:

Drug: Cold crystalloid infusions, 0.9%NaCl or Ringer's solution

RhinoChill

Active Comparator group

Description:

Nasopharyngeal cooling with the RhinoChill device (BeneChill, USA)

Treatment:

Device: RhinoChill